NCCN  	NCCN  	 NNP	B-NP
Oncology  	Oncology  	 NNP	I-NP
Risk  	Risk  	 NNP	I-NP
Evaluation  	Evaluation  	 NNP	I-NP
and  	and  	 CC	O
Mitigation  	Mitigation  	 NNP	B-NP
Strategies  	Strategies  	 NNP	I-NP
White  	White  	 NNP	O
Paper 	Paper 	 NNP	O
:  	:  	 :	O
Recommendations  	Recommendations  	 NNP	B-NP
for  	for  	 IN	I-NP
Stakeholders  	Stakeholders  	 NNP	I-NP
REMS  	REMS  	 NNP	I-NP
are  	are  	 VBP	O
a  	a  	 DT	O
particularly  	particularly  	 RB	O
important  	important  	 JJ	O
issue  	issue  	 NN	O
for  	for  	 IN	O
oncology  	oncology  	 NN	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
National  	National  	 NNP	B-NP
Comprehensive  	Comprehensive  	 NNP	I-NP
Cancer  	Cancer  	 NNP	I-NP
Network  	Network  	 NNP	I-NP
( 	( 	 -LRB-	O
NCCN 	NCCN 	 NNP	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
disproportionate  	disproportionate  	 JJ	O
number  	number  	 NN	O
of  	of  	 IN	O
drugs  	drugs  	 NNS	O
with  	with  	 IN	O
complex  	complex  	 JJ	O
REMS  	REMS  	 NNS	B-NP
are  	are  	 VBP	O
used  	used  	 VBN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
cancer  	cancer  	 NN	O
or  	or  	 CC	O
hematologic  	hematologic  	 JJ	B-NP
disorders 	disorders 	 NNS	I-NP
.  	.  	 .	O
REMS  	REMS  	 NNP	B-NP
policies  	policies  	 NNS	O
and  	and  	 CC	O
processes  	processes  	 NNS	O
within  	within  	 IN	O
oncology  	oncology  	 NNS	B-NP
may  	may  	 MD	O
act  	act  	 VB	O
as  	as  	 IN	O
a  	a  	 DT	O
model  	model  	 NN	O
for  	for  	 IN	O
other  	other  	 JJ	O
clinical  	clinical  	 JJ	B-NP
areas 	areas 	 NNS	I-NP
.  	.  	 .	O
A  	A  	 DT	O
breadth  	breadth  	 NN	O
of  	of  	 IN	O
experience  	experience  	 NN	O
and  	and  	 CC	O
access  	access  	 NN	O
to  	to  	 TO	O
a  	a  	 DT	O
wide  	wide  	 JJ	O
knowledge  	knowledge  	 NN	B-NP
base  	base  	 NN	I-NP
exists  	exists  	 VBZ	O
within  	within  	 IN	O
oncology  	oncology  	 NNS	B-NP
that  	that  	 WDT	O
will  	will  	 MD	O
ensure  	ensure  	 VB	O
appropriate  	appropriate  	 JJ	O
development  	development  	 NN	O
and  	and  	 CC	O
consideration  	consideration  	 NN	B-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
practical  	practical  	 JJ	I-NP
implications  	implications  	 NNS	I-NP
of  	of  	 IN	I-NP
REMS 	REMS 	 NNP	I-NP
.  	.  	 .	O
NCCN  	NCCN  	 NNP	B-NP
is  	is  	 VBZ	O
uniquely  	uniquely  	 RB	O
positioned  	positioned  	 VBN	O
to  	to  	 TO	O
assume  	assume  	 VB	O
a  	a  	 DT	O
leadership  	leadership  	 NN	B-NP
role  	role  	 NN	I-NP
in  	in  	 IN	O
this  	this  	 DT	O
process  	process  	 NN	O
given  	given  	 VBN	O
its  	its  	 PRP$	O
status  	status  	 NN	O
as  	as  	 IN	O
the  	the  	 DT	O
arbiter  	arbiter  	 NN	O
of  	of  	 IN	O
high-quality  	high-quality  	 JJ	B-NP
cancer  	cancer  	 NN	I-NP
care  	care  	 NN	I-NP
based  	based  	 VBN	O
on  	on  	 IN	O
its  	its  	 PRP$	O
world-leading  	world-leading  	 JJ	B-NP
institutions  	institutions  	 NNS	I-NP
and  	and  	 CC	O
clinicians 	clinicians 	 NN	B-NP
.  	.  	 .	O
Notwithstanding  	Notwithstanding  	 IN	O
the  	the  	 DT	O
potential  	potential  	 JJ	B-NP
benefits 	benefits 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
successful  	successful  	 JJ	O
design 	design 	 NN	O
,  	,  	 ,	O
implementation 	implementation 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
analysis  	analysis  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
FDA 	FDA 	 NNP	O
's  	's  	 POS	O
recent  	recent  	 JJ	O
requirement  	requirement  	 NN	O
for  	for  	 IN	O
REMS  	REMS  	 NNP	B-NP
for  	for  	 IN	O
some  	some  	 DT	O
high-risk  	high-risk  	 JJ	B-NP
drugs  	drugs  	 NNS	I-NP
and  	and  	 CC	O
biologics  	biologics  	 NNS	B-NP
will  	will  	 MD	O
present  	present  	 VB	O
significant  	significant  	 JJ	O
challenges  	challenges  	 NNS	O
for  	for  	 IN	O
stakeholders 	stakeholders 	 NN	B-NP
,  	,  	 ,	O
including  	including  	 VBG	B-NP
patients 	patients 	 NNS	I-NP
,  	,  	 ,	O
providers 	providers 	 NNS	O
,  	,  	 ,	O
cancer  	cancer  	 NN	B-NP
centers 	centers 	 NNS	I-NP
,  	,  	 ,	O
manufacturers 	manufacturers 	 NNS	B-NP
,  	,  	 ,	O
payors 	payors 	 NN	B-NP
,  	,  	 ,	O
health  	health  	 NN	B-NP
information  	information  	 NN	I-NP
technology  	technology  	 NN	I-NP
vendors 	vendors 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
regulatory  	regulatory  	 JJ	B-NP
agencies 	agencies 	 NNS	I-NP
.  	.  	 .	O
To  	To  	 TO	O
provide  	provide  	 VB	O
guidance  	guidance  	 VBN	O
to  	to  	 TO	O
these  	these  	 DT	O
stakeholders  	stakeholders  	 NN	B-NP
regarding  	regarding  	 VBG	I-NP
REMS  	REMS  	 NNP	I-NP
challenges 	challenges 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
NCCN  	NCCN  	 NNP	B-NP
assembled  	assembled  	 VBD	O
a  	a  	 DT	O
work  	work  	 NN	B-NP
group  	group  	 NN	I-NP
comprised  	comprised  	 NN	I-NP
of  	of  	 IN	I-NP
thought  	thought  	 NN	I-NP
leaders  	leaders  	 NNS	I-NP
from  	from  	 IN	O
NCCN  	NCCN  	 NNP	B-NP
Member  	Member  	 NNP	I-NP
Institutions  	Institutions  	 NNPS	I-NP
and  	and  	 CC	O
other  	other  	 JJ	O
outside  	outside  	 JJ	O
experts 	experts 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
Work  	Work  	 NNP	B-NP
Group  	Group  	 NNP	I-NP
identified  	identified  	 VBD	I-NP
challenges  	challenges  	 NNS	I-NP
across  	across  	 IN	O
the  	the  	 DT	O
REMS  	REMS  	 NNP	B-NP
spectrum 	spectrum 	 NN	I-NP
,  	,  	 ,	O
including  	including  	 VBG	O
the  	the  	 DT	O
areas  	areas  	 NNS	O
of  	of  	 IN	O
standardization 	standardization 	 NN	B-NP
,  	,  	 ,	O
development  	development  	 NN	O
and  	and  	 CC	O
assessment  	assessment  	 NN	O
of  	of  	 IN	O
REMS  	REMS  	 NNP	B-NP
programs 	programs 	 NNS	O
,  	,  	 ,	O
medication  	medication  	 NN	B-NP
guides 	guides 	 NNS	I-NP
,  	,  	 ,	O
provider  	provider  	 NN	B-NP
knowledge  	knowledge  	 NN	I-NP
and  	and  	 CC	O
impact  	impact  	 NN	O
on  	on  	 IN	O
prescribing 	prescribing 	 NN	O
,  	,  	 ,	O
provider  	provider  	 NN	B-NP
burden  	burden  	 NN	I-NP
and  	and  	 CC	O
compensation 	compensation 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
incorporation  	incorporation  	 NN	B-NP
of  	of  	 IN	I-NP
REMS  	REMS  	 NNP	I-NP
into  	into  	 IN	O
clinical  	clinical  	 JJ	B-NP
practice 	practice 	 NN	I-NP
.  	.  	 .	O
